Alimentation Couche-Tard Inc (ANCUF) 41.5499

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alimentation Couche-Tard Inc (ANCUF) 41.5499 $ANCUF

Couche-Tard will release its 2016 fourth quarter results on July 12th
CNW Group - Tue Jul 05, 11:00AM CDT
Alimentation Couche-Tard Inc. (TSX: ATD.A ATD.B), will be issuing on July 12(th), 2016 the financial results for its fourth quarter of 2016. Therefore, Couche-Tard invites analysts known to the Corporation to send their two questions to its management before 11:00 AM (DST) on July 12(th), 2016.

Couche-Tard Buys Assets of Premium 7 Network in Estonia
PR Newswire Europe - Mon Jun 20, 6:01AM CDT
LAVAL, Quebec, June 20, 2016 /PRNewswire/ --

Couche-Tard Completes the Acquisition of Shell's Retail Business in Denmark
CNW Group - Mon May 02, 6:00AM CDT
Alimentation Couche-Tard Inc. ("Couche-Tard" (TSX: ATD.A / ATD.B) announces it has closed the acquisition of A/S Dansk Shell's downstream retail business in Denmark, as previously announced on March 23, 2016. The transaction has received the appropriate regulatory approvals and all final closing requirements have been completed.

Couche-Tard Receives Approval to Acquire Shell's Retail Business in Denmark
CNW Group - Wed Mar 23, 6:23AM CDT
Alimentation Couche-Tard Inc. ("Couche-Tard" (TSX: ATD.A ATD.B) announces that it has received approval today from the European Commission for its deal to acquire A/S Dansk Shell's downstream retail business in Denmark, subject to divestment commitments. Completion of the acquisition is expected to occur in May 2016. It will be financed from Couche-Tard's available cash and existing credit facilities.

IIROC Trade Resumption - ATD.B
CNW Group - Tue Mar 15, 7:43AM CDT
Trading resumes in:

IIROC Trade Resumption - Alimentation Couche-Tard Inc.
Newsfile Corp - Tue Mar 15, 7:39AM CDT
Trading resumes in:

Alimentation Couche-Tard announces its results for its third quarter of fiscal year 2016
CNW Group - Tue Mar 15, 7:25AM CDT
For its third quarter ended January 31, 2016, Alimentation Couche-Tard Inc. (TSX: ATD.A ATD.B) announces net earnings of $274.0 million or $0.48 per share on a diluted basis. The results for the third quarter of fiscal 2016 were affected by a $27.2 million pre-tax curtailment gain on defined benefits pension plans obligation, a $22.9 million income tax expense stemming from an internal reorganization, a $10.4 million pre-tax write-off charge in connection with a fuel rebranding project, a $10.1 million pre-tax accelerated depreciation and amortization expense in connection with the Corporation's global brand initiative, a $9.2 million pre-tax charge on early termination of certain fuel supply contracts as well as a $4.1 million pre-tax net foreign exchange loss. Results from the third quarter of fiscal 2015 included a $16.6 million pre-tax net foreign exchange loss, a $16.1 million income tax expense stemming from an internal reorganization, a $10.4 million pre-tax loss from the disposal of the aviation fuel business, a $8.1 million pre-tax restructuring expense, a $2.6 million pre-tax curtailment gain on defined benefits pension plans obligation as well as a $0.6 million pre-tax negative goodwill. Excluding these items as well as acquisition costs from both comparable quarters' results, adjusted diluted net earnings per share would have been $0.53 for the third quarter of fiscal 2016, an increase of 3.9% compared with adjusted diluted net earnings per share of $0.51 for the third quarter of fiscal 2015. This increase is mainly attributable to the solid contribution from acquisitions and to continued strong organic growth. These items were partially offset by lower road transportation fuel margins in the U.S., by higher operating expenses to support Couche-Tard's strong organic growth, by the negative net impact from the translation of revenues and expenses from Couche-Tard's Canadian and European operations into US dollars as well as by the impact of the higher income tax rate. All financial information is in US dollars unless stated otherwise.
STO: 17.08 (+0.04)

IIROC Trade Halt - Alimentation Couche-Tard Inc.
Newsfile Corp - Tue Mar 15, 7:22AM CDT
The following issues have been halted by IIROC:

IIROC Trading Halt - ATD.B
CNW Group - Tue Mar 15, 7:18AM CDT
The following issues have been halted by IIROC:

Couche-Tard Signs Agreement to Buy Imperial Oil Retail Assets in Ontario and Québec
CNW Group - Tue Mar 08, 4:06PM CST
Alimentation Couche-Tard Inc. ("Couche-Tard" (TSX: ATD.A ATD.B) announces today that it has signed, through its whollyâ??owned indirect subsidiaries Mac's Convenience Stores Inc. and Couche-Tard Inc., an agreement with Imperial Oil ("Imperial" to acquire certain of its Canadian retail assets located in the Provinces of Ontario and Québec.

Couche-Tard will release its 2016 third quarter results on March 15th
CNW Group - Mon Mar 07, 12:45PM CST
Alimentation Couche-Tard Inc. (TSX: ATD.A ATD.B), will be issuing on March 15(th), 2016 the financial results for its third quarter of 2016. Therefore, Couche-Tard invites analysts known to the Corporation to send their two questions to its management before 11:00 AM (EDT) on March 15(th), 2016.

Couche-Tard completes acquisition of Topaz in Ireland
PR Newswire - Mon Feb 01, 7:06AM CST
Alimentation Couche-Tard Inc. ("Couche-Tard" (TSX: ATD.A ATD.B) confirms that it has closed the acquisition of Topaz Energy Group Ltd. in Ireland ("Topaz" as previously announced in December. The transaction has received the appropriate regulatory approvals and all final closing requirements have been completed.

Couche-Tard Welcomes Claude Tessier as Chief Financial Officer
PR Newswire - Mon Jan 25, 4:23PM CST
Alimentation Couche-Tard Inc. ("Couche-Tard" (TSX: ATD.A/ATD.B) announces today the appointment of Mr. Claude Tessier as its Chief Financial Officer, with effect from January 28, 2016. Mr. Tessier is a retail industry veteran and joins us from Canadian grocer Sobeys Inc., where he was President of the IGA Operations Business Unit.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 17

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 311

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 35

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 68

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 147

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 0

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 113

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Preeclampsia: Key Insights for Expecting Parents

Updated Category News Views 46

Preeclampsia: Essential Insights for Expecting Parents Preeclampsia is a significant condition that often raises concerns among expecting parents. It manifests as a dangerous form of high blood pressure during pregnancy and can also surface postpartum. Understanding this condition is vital for ensuring the health and safety of both mother and child during this crucial...

Continue Reading
DTE Energy Enhances Reliability with Smart Grid Technology

Updated Category News Views 240

DTE Energy's Progress with Smart Grid Technology DTE Energy (NYSE:DTE) has announced impressive strides in enhancing energy reliability through its cutting-edge smart grid technology. This initiative has successfully prevented nearly 5,000 power interruptions and saved over 1.8 million outage minutes for customers this year, highlighting the technology's role in ensuring...

Continue Reading
Key Insider Transactions in Major US Companies Unveiled

Updated Category News Views 270

Significant Insider Trading Activities This article sheds light on the notable insider buying and selling events reported recently, reflecting the movements within major US stocks. Major Insider Purchases Berkshire Hathaway Inc. (NYSE: BRKa) has made headlines by increasing its stake in Verisign Inc. (NASDAQ: VRSN). Under the leadership of Warren E. Buffett, the company...

Continue Reading
Hull Tactical's Latest Research Paper Enhances Market Predictions

Updated Category News Views 135

Hull Tactical Releases Innovative Academic Research The Hull Tactical team is excited to unveil its latest academic paper, titled Micro Alphas, co-authored by a talented group including Blair Hull, Petra Bakosova, Francois Cocquemas, Euan Sinclair, and Petri Fast. This research introduces a fresh framework that focuses on utilizing weak yet collectively informative...

Continue Reading
Cyrano Therapeutics and KYORIN Join Forces for Smell Loss Treatment

Updated Category News Views 138

Cyrano Therapeutics and KYORIN Collaboration Overview Cyrano Therapeutics, a pioneer in regenerative medicine, has taken a significant step forward in addressing the challenge of post-viral loss of smell. The company has entered into an option agreement with KYORIN Pharmaceutical Co., Ltd. to develop CYR-064, a promising treatment candidate specifically designed for those...

Continue Reading